Current Report Filing (8-k)
November 13 2017 - 7:47AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 13, 2017
NEKTAR
THERAPEUTICS
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
455
Mission Bay Boulevard South
San
Francisco, California 94158
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (415) 482-5300
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01
Other Events
On
November 11, 2017, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release announcing interim
data from the dose-escalation phase of the PIVOT-02 Phase 1/2 study, which is designed to evaluate the combination of Nektar’s
CD122-biased agonist, NKTR-214, with nivolumab across several tumor types. A copy of the press release announcing these interim
data is attached as Exhibit 99.1 to this Current Report on Form 8-K.
On
November 7, 2017, Nektar, announced that it would host an analyst and investor event at the 2017 Society for Immunotherapy of
Cancer Annual Meeting. The event was held on Saturday, November 11, 2017 at 6:15 p.m. Eastern Time, and included a presentation
and discussion of updated clinical data for the company's CD122-biased agonist, NKTR-214. Data from the PIVOT-02 Phase 1/2
study was reviewed at the event, as well as data from the Phase 1 dose-escalation study of NKTR-214 in combination with nivolumab
in patients with melanoma, renal cell carcinoma and non-small cell lung cancer. Presenters included Dr. Patrick Hwu of MD
Anderson Cancer Center, Dr. Adi Diab of MD Anderson Cancer Center, Dr. Michael E. Hurwitz of Yale
Cancer Center, Dr. Antoni Ribas of UCLA Medical Center and Dr. Nizar M. Tannir of MD Anderson
Cancer Center. A recording of this analyst and investor event is available for replay for two weeks on Nektar’s website,
www.nektar.com
At
the analyst and investor event, Nektar made certain forward-looking statements regarding the potential therapeutic benefit of
NKTR-214 for cancer patients, the future clinical development plans for NKTR-214, the potential of NKTR-214 in combination with
other immunotherapy agents including Bristol-Myers Squibb’s Opdivo (nivolumab), and certain other statements regarding the
prospects and potential of Nektar’s business, technology platform and drug candidate pipeline. These forward-looking statements
involve substantial risks and uncertainties, including but not limited to: (i) our statements regarding the therapeutic potential
of NKTR-214 in combination with Opdivo are based on findings and observations from ongoing clinical studies and these findings
and observations will evolve over time as more data emerges from the studies; (ii) NKTR-214 is in early stage clinical development
and the risk of failure remains high and failure can unexpectedly occur due to efficacy, safety or other unpredictable factors;
(iii) the initial preliminary RECIST response data presented at the event is subject to change—in particular, there is no
way to predict whether unconfirmed responses will become confirmed responses as the clinical studies progress; (iv) the preliminary
clinical results from the NKTR-214 clinical studies presented at the event remain subject to change as a result of final data
audit confirmation procedures to be conducted following completion of the studies; (v) the timing of the commencement or end of
clinical studies and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated
patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design,
clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important
markets; (vi) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of applying
our technology platform to potential new drug candidates (such as NKTR-214) is therefore highly uncertain and unpredictable and
one or more research and development programs could fail; (vii) patents may not issue from our patent applications for our drug
candidates including NKTR-214, patents that have issued may not be enforceable, or additional intellectual property licenses from
third parties may be required; and (viii) certain other important risks and uncertainties set forth in our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission on November 8, 2017. Any forward-looking statement made by Nektar
at the investor and analyst event will be based only on information currently available to Nektar and speaks only as of the date
on which it is made. Actual results could differ materially from the forward-looking statements made at the investor and analyst
event. Nektar undertakes no obligation to update forward-looking statements whether as a result of new information, future events
or otherwise.
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
|
|
|
By:
|
|
/s/
Mark A. Wilson
|
|
|
|
Mark
A. Wilson
|
|
|
|
General
Counsel and Secretary
|
|
|
|
|
Date:
|
|
November
13, 2017
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Sep 2023 to Sep 2024